Skip to content
2000
Volume 11, Issue 4
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.

Loading

Article metrics loading...

/content/journals/chamc/10.2174/1871525712666140321095519
2013-12-01
2025-12-16
Loading full text...

Full text loading...

/content/journals/chamc/10.2174/1871525712666140321095519
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test